Pfizer Biohaven Acquisition Sparks Hope of More Biotech M&A

Earlier this week, Pfizer (NYSE:PFE) announced plans to acquire Biohaven Pharmaceutical (NASDAQ:BHVN) for $11.6 billion, sparking hopes of more biotechnology consolidation activity to come. Pfizer is paying a 33% premium for the maker of Nurtec ODT, a well-known migraine headache treatment. The...
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.